Experienced in Glomus Jugulare Tumor

Dr. Zachary S. Zumsteg

Radiation Oncology
Cedars-Sinai Medical Center
8700 Beverly Blvd, 
West Hollywood, CA 
Offers Telehealth
Experienced in Glomus Jugulare Tumor
Cedars-Sinai Medical Center
8700 Beverly Blvd, 
West Hollywood, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Zachary Zumsteg is a Radiation Oncologist in West Hollywood, California. Dr. Zumsteg is rated as an Experienced provider by MediFind in the treatment of Glomus Jugulare Tumor. His top areas of expertise are Prostate Cancer, Laryngeal Cancer, Throat Cancer, Prostatectomy, and Thyroidectomy.

His clinical research consists of co-authoring 127 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Hospital Affiliations
Cedars-Sinai Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

CEDARS-SINAI MEDICAL CENTER
8700 Beverly Blvd, West Hollywood, CA 90048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Radiation, Procedure
Study Phase: Early Phase 1
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
View 7 Less Clinical Trials

127 Total Publications

AJCC9V classification for HPV-positive oropharyngeal carcinoma - Authors' reply.
AJCC9V classification for HPV-positive oropharyngeal carcinoma - Authors' reply.
Journal: The Lancet. Oncology
Published: September 10, 2025
Similar Doctors
Advanced in Glomus Jugulare Tumor
Dr. Tania B. Kaprealian
Radiation Oncology
Advanced in Glomus Jugulare Tumor
Dr. Tania B. Kaprealian
Radiation Oncology

The Regents Of The University Of California

200 Ucla Med Plaza, B265, 
Los Angeles, CA 
 (3.8 miles away)
310-825-9304
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tania Kaprealian is a Radiation Oncologist in Los Angeles, California. Dr. Kaprealian is rated as a Distinguished provider by MediFind in the treatment of Glomus Jugulare Tumor. Her top areas of expertise are Meningioma, Schwannoma, Acoustic Neuroma, Radiation Induced Meningioma, and Thalamotomy.

Experienced in Glomus Jugulare Tumor
Dr. Albert C. Mak
Radiation Oncology
Experienced in Glomus Jugulare Tumor
Dr. Albert C. Mak
Radiation Oncology

Albert C Mak MD Inc

707 S Garfield Ave, Suite B002, 
Alhambra, CA 
 (14.8 miles away)
626-227-2777
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Albert Mak is a Radiation Oncologist in Alhambra, California. Dr. Mak is rated as an Advanced provider by MediFind in the treatment of Glomus Jugulare Tumor. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Primitive Neuroectodermal Tumor (PNET), and Posterior Fossa Tumor.

Experienced in Glomus Jugulare Tumor
Dr. Geoffrey A. Geiger
Radiation Oncology | Hematology | Oncology
Experienced in Glomus Jugulare Tumor
Dr. Geoffrey A. Geiger
Radiation Oncology | Hematology | Oncology

The Oncology Institute Ca, A Professional Corporation

554 E San Bernardino Rd, Suite 105, 
Covina, CA 
 (28.7 miles away)
626-331-6866
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Geoffrey Geiger is a Radiation Oncologist and a Hematologist in Covina, California. Dr. Geiger is rated as an Experienced provider by MediFind in the treatment of Glomus Jugulare Tumor. His top areas of expertise are Adenoid Cystic Carcinoma, Glomus Jugulare Tumor, Acinic Cell Carcinoma of Salivary Glands, Salivary Gland Tumors, and Gamma Knife Radiosurgery. Dr. Geiger is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zumsteg's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile